Polylaminin: Brazilian drug promises to regenerate spinal cord injury and restore movement
Rio de Janeiro, Brazil - A scientific discovery developed over more than 25 years is on the verge of transforming the treatment of spinal cord injuries. Scientists from Federal University of Rio de Janeiro (UFRJ), in partnership with the Cristália laboratory, announced polylaminine, an innovative drug that has been shown to partially or totally restore movement in patients with spinal cord injury, something that until now was seen as unlikely in many cases.
What is polylaminin and how does it work in spinal cord injury?
Researchers developed polylaminin from laminin, a protein present in the development of the nervous system and extracted from the human placenta.
It therefore works by promoting the regeneration of mature neurons and inducing the formation of new ones axons, These are the “wires” that transmit electrical signals from the brain to the body. This nerve recovery can re-establish communication broken by spinal injuries.
Initial evidence in humans and animals with spinal cord injury
In studies with animalsIn dogs with old spinal cord injuries, four of the six treated significantly regained mobility; in rats, effects were observed within the first 24 hours.
In human patients in the experimental phase: around 8-10 volunteers with spinal cord injuries caused by accidents, falls or gunshots received the application; some recovered full or partial movement. Examples include men aged 31 and 33, as well as a 27-year-old woman.
Important: Polylamine shows the best results when applied up to 24 hours after the trauma, although it also benefits older injuries.
Safety, production and regulation of polylamine treatment
Cristália is starting commercial-scale production of polylaminine at its biotechnology plant in Itapira, using raw materials (donated placentas) collected in accordance with regulations.
The research is led by Tatiana Coelho de Sampaio, from UFRJ, with support from FAPERJ and other institutions. A partnership with Cristália was formalized in 2018.
However, the treatment still depends on the approval of National Health Surveillance Agency (ANVISA) to move on to larger regulatory clinical studies.
There is official registration of the clinical trial in Brazil: prospective randomized study to evaluate the safety and efficacy of polylamine in acute spinal cord injuries. Plataforma Brasil / REBEC.
Why polylamine could mark a watershed in regenerative medicine for spinal cord injury
The arrival of polylamine is not just another drug in the testing phase; it could usher in a new paradigm in the care of patients with spinal cord injury. Until now, medicine looked for alternatives such as stem cells or experimental surgery, often at high cost and with uncertain results. Now, initial studies indicate that this protein could simplify treatment and increase the chances of rehabilitation. Among the factors that reinforce this potential are, for example:
- Recovery of motor functions, the real possibility of restoring lost movements in paraplegia or tetraplegia.
- Critical intervention time, Early application (up to 24 hours) shows better results.
- Less invasive treatment than cell therapies, A “safer and more affordable” alternative to stem cells, according to researchers.
- Local development, global benefits, Brazilian research can export knowledge and treatment, with a strong social impact, including for the SUS.
Limitations, challenges and next steps for polylaminin in the case of spinal cord injury
Need more data on human clinical trials with larger numbers of patients, to confirm efficacy and safety.
- Logistics: rapid diagnosis and a hospital structure capable of providing treatment immediately after the trauma.
- Physiotherapy and physical rehabilitation remain indispensable, polylamine alone will not solve the problem.
- Evaluation of effects on chronic (older) lesions is still uncertain.
Polylaminin signals the beginning of a new era for spinal cord injury
Polylaminin holds real promise for the regeneration of spinal cord injury, This drug has been shown to have a positive effect on motor function, with cases of motor recovery never before documented in Brazilian studies. Therefore, if the clinical trials confirm the initial findings, this drug could redefine treatment standards in paraplegia and tetraplegia, restoring hope and autonomy to those suffering from irreversible loss of movement.

Share on:
Se inscrever
Login
2 Comments
Mais Votado
Mais Recente
Mais Antigo
Feedbacks Inline
Ver todos os comentários